Aventis Sees “Blurring” Of Rx/OTC Distinctions; Change Coming For Allegra?

The antihistamine market can no longer comfortably be divided between prescription and OTC entrants, Aventis Chief Operating Officer Richard Markham suggested during the J.P. Morgan health care conference in San Francisco Jan. 13

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet